ALK-positive non-small-cell lung cancer
Clinical trials for ALK-positive non-small-cell lung cancer explained in plain language.
Never miss a new study
Get alerted when new ALK-positive non-small-cell lung cancer trials appear
Sign up with your email to follow new studies for ALK-positive non-small-cell lung cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill shows promise against tough lung cancer
Disease control Recruiting nowThis study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Phase 1/2 • Sponsor: TRIANA Biomedicines, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug combo outsmart resistant lung cancer?
Disease control Recruiting nowThis trial is testing whether adding an experimental drug called NXP900 to the standard treatment lorlatinib can help people with advanced ALK-positive non-small cell lung cancer. The study includes adults who have already been treated with lorlatinib and whose cancer has not bee…
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New ALK inhibitor NVL-655 enters trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called neladalkib (NVL-655) in people with advanced ALK-positive non-small cell lung cancer and other solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well it shrinks tumors. Up to 840 participants will be en…
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Phase 1/2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Antidepressant may ease brain fog from lung cancer drug
Symptom relief Recruiting nowThis study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New program aims to ease distress for advanced lung cancer patients
Symptom relief Recruiting nowThis study is testing a new program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage their cancer. Re…
Matched conditions: ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC